新規診断された遠隔転移非小細胞肺癌患者におけるゲノムバイオマーカー特定のための包括的な遊離DNA解析の臨床的有用性

Leighlら（Mon,）がこの問題を研究しました。

www.synapsesocial.com/papers/699ea8a3d8a7e1a4e1facfe5 — DOI: https://doi.org/10.1158/1078-0432.ccr-19-0624

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Abstract 4272: A novel approach to differentiation of somatic vs. germline variants in liquid biopsies using a betabinomial model· 2018 · 13 citations
2. Comprehensive molecular profiling of lung adenocarcinoma· 2014 · 5,800 citations
3. Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model.· 2018 · 43 citations
4. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer· 2015 · 242 citations
5. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial· 2016 · 442 citations